Zhaoke Ophthalmology Limited announced that patient enrollment was completed for the two-year Phase III clinical trial and the concurrent one-year Phase III bridging clinical trial of one of the Company's core products, NVK002, on July 21, 2022 and July 28, 2022 respectively. The main objective of the China CHAMP and Mini-CHAMP is to evaluate the efficacy and safety of NVK002 in the treatment of myopia progression in children and adolescents. Led by Professor Wang Ning Li from Beijing Tongren Hospital as the Principal Investigator, the China CHAMP trial involves 19 centers and has completed the enrollment of 777 patients in less than 4 months and is 2 months ahead of schedule.

Co-led by Professor Qu Xiao Mei from Eye and ENT Hospital of Fudan University and Professor Yang Xiao from Zhongshan Ophthalmic Center, Sun Yat-Sen University as the Principal Investigators, the Mini-CHAMP trial involves 18 centers and has completed the enrollment of 526 patients in less than 3 months and is 3 months ahead of schedule. Completion of the enrollment of these two Phase III trials puts the Company at the forefront in the development of drug treatment for myopia progression in China. In the United States and Europe, the Company's partner, Vyluma Inc, has been conducting parallel Phase III clinical trial ­ CHAMP ­ with three years of NVK002 treatment which is expected to complete before the end of 2022.

A New Drug Application ("NDA") submission to the US Food and Drug Administration (the "FDA") is expected in 2023 and NVK002 is currently positioned as the first clinically-proven pharmaceutical product approved for treating the progression of myopia in the world.